Diverse Opportunities, Focused Approach

Messenger RNA Therapeutics™ can be applied to meet patient needs across a broad range of diseases.

We have focused intensively on supporting the efforts of our partners, AstraZeneca, Alexion and DARPA in the areas of cardiovascular, oncology, rare disease and biodefense.

For our own programs, we will form ventures to focus in key disease areas where high unmet medical needs demand safe, efficacious, and innovative therapies. Onkaido Therapeutics is our first venture company, formed, funded and wholly-owned by Moderna, and focused exclusively on the advancement of oncology products for previously undruggable targets and as a superior alternative to existing drug modalities. Further ventures are being formed and staffed.

Moderna has completed numerous in vivo proof-of-concept studies. We have shown that messenger RNA Therapeutics™ can successfully induce in vivo production of dozens of effector proteins through intra-muscular, subcutaneous, and intravenous administration; and have demonstrated safety and efficacy in multiple preclinical models, including non-human primates.

We can generate and test new drug candidates of messenger RNA Therapeutics™ in animals in a matter of weeks, dramatically accelerating the speed of drug development, as well as reducing the cost and risk traditionally associated with discovering and delivering new medicines to patients. This speed, and the flexibility of our enabling technology to address any number of diseases, is giving rise to a robust portfolio of therapeutic candidates.

Moderna Therapeutics Pipeline